Novel Process Platform for the Manufacturing and Purification of Biosimilar rHu Ranibizumab

• Economical production of antibody fragment with higher yield
• Simple & cost-effective purification (reduced number of unit operations)
• A two-fold increase in productivity due to integrated multimode chromatography over existing processes

• Age-related macular degeneration
• Diabetic retinopathy

• CSIR-NCL scientists have developed a novel process platform for the manufacturing & purification of a biosimilar rHu Ranibizumab
• A novel cloning, expression & refolding platform
• Integrated continuous multimodal chromatography for purification
• A two-fold increase in productivity over the existing processes
• Biosimilarity has been demonstrated with Lucentis